2018
Successful Vaccines
Abstract: Vaccines are considered one of the most important advances in modern medicine and have greatly improved our quality of life by reducing or eliminating many serious infectious diseases. Successful vaccines have been developed against many of the most common human pathogens, and this success has not been dependent upon any one specific class of vaccine since subunit vaccines, non-replicating whole-virus or whole-bacteria vaccines, and attenuated live vaccines have all been effective for particular vaccine target…
Search citation statements
Paper Sections
Select...
29
25
3
1
Citation Types
0
48
0
0
Year Published
2019
2026
Publication Types
Select...
50
5
1
1
Relationship
2
55
Authors
Journals
Cited by 57 publications
(48 citation statements)
References 163 publications
0
48
0
0
“…Waning antibody responses and loss of protective efficacy over time are limitations common to many vaccines 70 . As such, we sought to explore whether megakaryocyte-dependent mechanisms of antibody response durability were conserved in response to other vaccines.…”
Section: Results
mentioning
confidence: 99%
“…Waning antibody responses and loss of protective efficacy over time are limitations common to many vaccines 70 . As such, we sought to explore whether megakaryocyte-dependent mechanisms of antibody response durability were conserved in response to other vaccines.…”
Section: Results
mentioning
confidence: 99%
“…5 ). Because nAbs are a prominent surrogate for protective immunity induced by multiple successful viral vaccines, 21 this finding suggests that the VSVΔG-LASV-GPC human vaccine candidate has the potential to provide broad protection against LASV from different geographical regions. In agreement with observing broad neutralization activity, serum antibodies from animals vaccinated in this study were found to target key conserved structures on the LASV GPC trimer (Enriquez, Hastie et al., unpublished, submitted companion manuscript published in this issue ).…”
Section: Discussion
mentioning
confidence: 99%
“…Indeed, most vaccines approved for human use against other pathogens identify neutralising antibodies as a primary correlate of protection. 55 Neutralising antibodies against LASV, however, have been historically difficult to elicit, either by vaccination or natural infection. Indeed, serum samples collected during prior LASV vaccine preclinical studies were typically non- or only weakly neutralising overall.…”
Section: Discussion
mentioning
confidence: 99%
